Genetic Polymorphisms and Cisplatin- Related Nephrotoxicity
Open Access
- 7 January 2015
- journal article
- Published by Peertechz Publications Private Limited in Global Journal of Cancer Therapy
- Vol. 1 (1), 001-004
- https://doi.org/10.17352/gjct.000001
Abstract
No abstract availableThis publication has 39 references indexed in Scilit:
- Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumoursBritish Journal of Cancer, 2013
- Association between Single Nucleotide Polymorphisms (SNPs) and Toxicity of Advanced Non-Small-Cell Lung Cancer Patients Treated with ChemotherapyPLOS ONE, 2012
- Mechanisms of Cisplatin NephrotoxicityToxins, 2010
- Glutathione Pathway Genetic Polymorphisms and Lung Cancer Survival After Platinum-Based ChemotherapyCancer Epidemiology, Biomarkers & Prevention, 2010
- Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)British Journal of Pharmacology, 2010
- Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomesPharmacogenetics and Genomics, 2009
- Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced NephrotoxicityClinical Pharmacology & Therapeutics, 2009
- Glutathione S-transferase M1 and T1 polymorphisms may predict adverse effects after therapy in children with medulloblastomaNeuro-Oncology, 2009
- The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicityAmerican Journal of Physiology-Renal Physiology, 2009
- The Role of the Mammalian Copper Transporter 1 in the Cellular Accumulation of Platinum-Based DrugsMolecular Pharmacology, 2008